Background:Neuroprotection, as a therapeutic strategy for patients under recovery after TBI, is not universally accepted, consequently is not widely. Throughout these two studies we comparatively assess neurorestorative, including neurorehabilitative, outcomes obtained with or without Cerebrolysin®.
Scope and study design:This was a retrospective case-control study that was approved by the bioethics commission of the Bagdasar-Arseni Teaching Emergency Hospital, Bucharest, Romania. The aim of the study was to comparatively assess neurorestorative, including neu¬rorehabilitative, outcomes obtained with or without Cerebrolysin®.
Materials and methods:Nineteen cases treated with Cerebrolysin versus 28 who did not receive this drug were included in this study. First we studied 47 patients with TBI all in subacute state, admitted between January 2005 and December 2010, than 120 patients with different states since TBI admitted in the same period 2005-2010, which receive (studied lot) or not (control lot) neuroprotection.
Results:Cerebrolysin used for short period, only in subacute state, is not statistical significant in improving psycho–cognitive and functional parameters we evaluated ( FIM, GOS, Rankin, number of days untill the functional knee extension recovery, KE, untill walk between parallels bars, WPB, cane assisted walk CW, etc, totally 9 parameters). Neuroprotection with Cerebrolysin used during the next steps of rehabilitation admission, increase significant statistically functional benefit of the patient (difference FIM upon discharge – FIM upon admission 48: 25.08, p value being p<0,001), hastensneuro-psycho-motor performances (patients block knee faster 8:10, p<0,001, WPB faster 8>12, p<0,001, CW faster 7:13, p<0,001) and is dose dependent (difference FIM dis. -FIM adm is statistically significant only with patients treated with 20 ml Cerebrolysin/ day, average 53,17, p=0,047).
Discussion and conclusion:The clinical/functional evolution, comparatively evaluated in the studied inpatients, suggest that Cerebrolysin, correctly indicated and administered, may perhaps contribute to some improvement of post-TBI patients’overall neurorestorative/rehabilitative outcome, used not only in post acute state after TBI, but also during the next phases of rehabilitation.
View full abstract